Comparison
Cagrilintide vs. Epitalon
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Research other
CAS no.
1415456-99-3
307297-39-8
Molecular weight
4253.7 g/mol
390.35 g/mol
Half-life
168 h
0.3 h
Sequence
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYAla-Glu-Asp-GlyMechanism of action
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
Epitalon
Postulated mechanisms include modulation of gene expression in pinealocytes, telomerase activation (observed in cell culture studies) and influence on melatonin synthesis. A defined primary receptor is not established; the mechanistic basis rests on in-vitro and animal data from the Khavinson group.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
4
4
of which in humans
3
1
Effects recorded
3
4
Open conflicts
0
1
Documented adverse events
1
1